2015 Press Releases

Keyword Search
 

2017 | 2016 | 2015
DateTitle 
12/01/15Avinger Announces Filing of 510(k) Application for Enhanced Version of Pantheris(TM)
REDWOOD CITY, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that it has filed a 510(k) pre-market notification with the U.S. Food and Drug Administration (FDA) for an enhanced version of its Pantheris™Catheter. On October 14, 2015, Avinger received 510(k) clear... 
Printer Friendly Version
11/24/15Avinger, Inc. to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company plans to participate in two upcoming investor conferences. Avinger's management is scheduled to participate in the Evercore ISI MedTools & Outsourcing Investor Forum in Boston, MA on Th... 
Printer Friendly Version
11/05/15Avinger, Inc. Announces Third Quarter 2015 Results
Received FDA Clearance for Pantheris™ Accelerated Expansion of Installed Base of Lumivascular Platform REDWOOD CITY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the third quarter ended September 30, 2015. Recent Highlights Received ... 
Printer Friendly Version
11/03/15Avinger, Inc. to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company will be participating in two upcoming investor conferences. Avinger's management is scheduled to present at the Stephens Fall Investment Conference in New York City, NY on Tuesday, November ... 
Printer Friendly Version
11/02/15Avinger Successfully Completes VISION IDE Trial for Pantheris(TM)
Final Six-Month VISION Data Presented at VIVA 2015 REDWOOD CITY, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that its Pantheris™ system has achieved all safety and efficacy endpoints in six-month follow-up data for its VISION IDE clinical trial. VISION was desig... 
Printer Friendly Version
10/22/15Avinger, Inc. to Announce Third Quarter 2015 Results on Thursday, November 5, 2015
Conference Call Scheduled for Thursday, November 5, 2015 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, today announced that it will release its financial results for the third quarter of 2015 after the close of trading on Thursday, November 5... 
Printer Friendly Version
10/14/15Avinger, Inc. Receives FDA 510(k) Clearance for Pantheris(TM)
Image-Guided Atherectomy Device Cleared to Treat Patients Suffering From PAD REDWOOD CITY, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to commence U.S. commercializa... 
Printer Friendly Version
10/13/15Avinger Announces Interim Six-Month VISION Trial Results at TCT 2015
Primary Safety and Efficacy Endpoints Achieved Target Lesion Revascularization Rate Equals 10.8% SAN FRANCISCO, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced interim six-month results for its VISION clinical trial. VISION is designed to evaluate the safety and eff... 
Printer Friendly Version
09/23/15Avinger, Inc. Secures Up to $55M in Financing From CRG
Financing to Support Commercial Launch of Pantheris(TM) REDWOOD CITY, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, announced today that it has entered into a term loan agreement and a securities purchase agreement with CRG (formerly Capital Royalty L.P.). The agreements provid... 
Printer Friendly Version
08/12/15Avinger, Inc. Announces Early 510(k) Filing for Pantheris(TM)
REDWOOD CITY, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, announced it will file a submission today with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market its Pantheris image-guided atherectomy device for the treatment of patients with peripheral arteri... 
Printer Friendly Version
07/30/15Avinger, Inc. Announces Participation in Canaccord Genuity 35th Annual Growth Conference
REDWOOD CITY, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that the Company plans to participate in the Canaccord Genuity 35th Annual Growth Conference in Boston. Avinger management is scheduled to present on Thursday, August 13, 2015 at 9:00am ET. Interested ... 
Printer Friendly Version
07/28/15Avinger, Inc. Announces Second Quarter 2015 Results
Achieved Positive 30-Day Results for Clinical Trial for Pantheris™ Expanded Installed Base of Company's Lumivascular Platform REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the second quarter ended June 30, 2015. Recent Highligh... 
Printer Friendly Version
07/20/15Avinger, Inc. to Announce Second Quarter 2015 Results on Tuesday, July 28, 2015
Conference Call Scheduled for Tuesday, July 28, 2015 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that it will release its financial results for the second quarter of 2015 after the close of trading on Tuesday, July 28, 2015.... 
Printer Friendly Version
05/20/15Avinger Announces 30-Day VISION Trial Results at EuroPCR 2015
Primary Efficacy Endpoint Achieved With Encouraging Early Safety Results PARIS, May 20, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced 30-day interim results for its VISION clinical study. VISION is designed to evaluate the safety and efficacy of the Pantheris™ system to perform d... 
Printer Friendly Version
05/06/15Avinger, Inc. Announces First Quarter 2015 Results
Achieves Primary Efficacy Endpoint in VISION Clinical Trial for Pantheris(TM) REDWOOD CITY, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported financial results for the first quarter ended March 31, 2015. Recent Highlights Achieved primary efficacy endpoint i... 
Printer Friendly Version
04/22/15Avinger, Inc. to Announce First Quarter 2015 Results on Wednesday, May 6, 2015
Conference Call Scheduled for Wednesday, May 6, 2015 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that it will release its financial results for the first quarter of 2015 after the close of trading on Wednesday, May 6, 2015.... 
Printer Friendly Version
04/06/15Avinger, Inc. Names John Borrell as Vice President of Sales
REDWOOD CITY, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that John Borrell has been named Vice President of Sales, effective April 20, 2015. Mr. Borrell will report directly to Avinger's CEO, Jeff Soinski. Mr. Borrell joins Avinger with more than 25 years o... 
Printer Friendly Version
03/12/15Avinger, Inc. Announces Fourth Quarter and Full Year 2014 Results
REDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported financial results for the fourth quarter and year ended December 31, 2014. Recent Highlights Completed enrollment in VISION, a 133-patient clinical trial designed to evaluate the safety and ef... 
Printer Friendly Version
03/12/15Avinger, Inc. Completes Patient Enrollment for VISION Clinical Trial
Company Reaches Key Milestone for Pantheris(TM) Image-Guided Atherectomy Device REDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that it has completed enrollment of its VISION clinical study, which is designed to evaluate the safety and efficacy of th... 
Printer Friendly Version
02/26/15Avinger, Inc. to Announce Fourth Quarter and Full Year 2014 Results on Thursday, March 12, 2015
REDWOOD CITY, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq:AVGR) a manufacturer of image-guided, catheter-based systems used by physicians to treat peripheral arterial disease and pioneer of the lumivascular approach to treating vascular disease, today announced that it will release its financial results for the fourth quarter and full year of 2014 after the close of trading on Thursday, March 12, 2015. The Company will host a corresponding conference call beginning at 1:30pm... 
Printer Friendly Version
02/17/15Avinger, Inc. Announces Participation in Cowen 35th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) today announced that the company plans to participate in the Cowen and Company 35th Annual Health Care Conference in Boston. Avinger management is scheduled to present on Monday, March 2, 2015 at 2:50 pm ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger's website at www.avinger.com. The webcast replay will be available after the conclusion of ... 
Printer Friendly Version
02/04/15Avinger, Inc. Announces Closing of Upsized Initial Public Offering
REDWOOD CITY, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) today announced the closing of its underwritten initial public offering of 5,000,000 shares of its common stock at a public offering price of $13.00 per share. The Company originally filed to sell 4,615,384 shares. Avinger's common stock is listed on The NASDAQ Global Market under the trading symbol "AVGR." All shares of the common stock in this offering were offered by Avinger. Avinger estimates net proceeds from... 
Printer Friendly Version
01/30/15Avinger, Inc. Announces Pricing of Initial Public Offering
Redwood City, California, January 30, 2015  – Avinger, Inc. (NASDAQ: AVGR) today announced the pricing of its underwritten initial public offering of 5,000,000 shares of its common stock at a public offering price of $13.00 per share.  The company's shares are expected to begin trading on The NASDAQ Global Market on January 30, 2015 under the ticker symbol "AVGR."  Avinger has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common sto... 
Printer Friendly Version
01/14/15Avinger Appoints Thomas J. Fogarty, M.D. to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Avinger, Inc., a manufacturer of image-guided, catheter-based systems used by physicians to treat peripheral arterial disease and pioneer of the lumivascular approach to treating vascular disease, announced today that Thomas J. Fogarty, M.D. has been elected to its Board of Directors, effective December 31, 2014. An internationally recognized cardiovascular surgeon, inventor, and entrepreneur, Dr. Fogarty has been involved with a wide spectrum of innovatio... 
Printer Friendly Version
01/05/15James G. Cullen to Join Avinger’s Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Avinger, Inc., a manufacturer of image-guided, catheter-based systems used by physicians to treat peripheral arterial disease and pioneer of the lumivascular approach to treating vascular disease, announced today that James G. Cullen has been elected to its Board of Directors, effective December 30, 2014. The Board now consists of six directors. Cullen brings to the position extensive executive and board level expertise, as well as a passion for the advanc... 
Printer Friendly Version